Citation Impact
Citing Papers
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
2000 Standout
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Intraperitoneal chemotherapy: Analysis of complications with an implanted subcutaneous port and catheter system
1991
Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study
2015
Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review
1994
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres
2002 StandoutNobel
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
1991 Standout
Clinical trials in primary hepatocellular carcinoma: current status and future directions
1988
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
2002 Standout
Self-Assembling Drugs: A New Approach to Biochemical Modulation in Cancer Chemotherapy
1994
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications
2004 Standout
Cisplatin: mode of cytotoxic action and molecular basis of resistance
2003 Standout
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
2008 Standout
Dynamic Covalent Chemistry
2002 StandoutNobel
Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice
2002 StandoutNobel
Targeting Ferroptosis to Iron Out Cancer
2019 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy.
1987
Management of malignant pleural mesothelioma: a critical review
2000
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
2003 Standout
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
1999 Standout
Nanoparticles in cancer therapy and diagnosis
2002 Standout
Amifostine in clinical oncology: current use and future applications
2002
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2014 Standout
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
1996 Standout
A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.
1991
Molecular mechanisms of cisplatin resistance
2011 Standout
Management of Hepatocellular Carcinoma *
2005 Standout
Treatment of peritoneal carcinomatosis by continuous hyperthermic peritoneal perfusion with cisplatin
1996
The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG
2003
Polymer conjugates as anticancer nanomedicines
2006 Standout
Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil
1989
Block copolymer micelles for drug delivery: design, characterization and biological significance
2001 Standout
Clinical Pharmacokinetics of Doxorubicin
1988
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
2001 Standout
Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody
1999
Hypersensitivity reactions from antineoplastic agents
1987
Experimental and clinical studies on the intraperitoneal administration of cis-diamminedichloroplatinum (II) for peritoneal carcinomatosis caused by gastric cancers
1993
The pathobiology of mucositis
2004 Standout
Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2)
1999
Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia
2004
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin–DNA adduct formation in patients and ovarian cancer cell lines
1998
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
Oxidative Stress in Cancer
2020 Standout
Chemistry in living systems
2005 StandoutNobel
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
Hypersensitivity reactions from taxol.
1990 Standout
Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance
1999
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2020 Standout
A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: A southwest oncology group trial
1990
Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies.
1987
Non-thermal plasma induces a stress response in mesothelioma cells resulting in increased endocytosis, lysosome biogenesis and autophagy
2017
Collagen gel systems for sustained delivery and tissue engineering
2003 Standout
THE EFFECT OF REBAMIPIDE ON CISPLATIN-INDUCED NEPHROTOXICITY IN RATS
2000
The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: “Maintenance” therapy reconsidered
1992
Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo
1997
High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer
1990
Clinical Perspectives on Platinum Resistance
2000
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.
1996
WR2721 as a modulator of cisplatin-and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach
1993
Advances in Malignant Mesothelioma
2005 Standout
Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients
2013
The dawning era of polymer therapeutics
2003 Standout
Controlled cisplatin delivery system using poly(d,l-lactic acid]
1992
Minireview Magnetically controlled targeted micro-carrier systems
1989
Cancer of the Ovary
2004 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Clinical pharmacokinetics of doxorubicin in hepatoma patients after a single intravenous injection of free or nanoparticle-bound anthracycline
1989
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Review: Advances in Intraperitoneal (Intracavitary) Administration of Synthetic Polymers for Immunotherapy and Chemotherapy
1986
Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity
1986
Collagen chemoembolization: pharmacokinetics and tissue tolerance of cis-diamminedichloroplatinum(II) in porcine liver and rabbit kidney.
1988
Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis
1986
Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors
1989 Standout
The Tumor Lysis Syndrome
2011 Standout
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Review: Practical considerations in ovarian cancer chemotherapy
2010
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Cisplatin-induced renal toxicity
1997
INTRAPERITONEAL CHEMOTHERAPY
1994
Clinical Science Review: The Routinization of Intraperitoneal (Intracavitary) Chemotherapy and Immunotherapy
1986
Asymmetric Catalysis by Architectural and Functional Molecular Engineering: Practical Chemo- and Stereoselective Hydrogenation of Ketones
2001 StandoutNobel
Dynamic Combinatorial Chemistry
2006 Standout
Generation of Candidate Ligands for Nicotinic Acetylcholine Receptors via in situ Click Chemistry with a Soluble Acetylcholine Binding Protein Template
2012 StandoutNobel
Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?
1999
Intraperitoneal therapy in the management of ovarian carcinoma.
1990
Biodegradation and biocompatibility of PLA and PLGA microspheres
1997 Standout
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
2018 Standout
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Peritoneal carcinomatosis: Anatomy, physiology, diagnosis, management
1986
Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma
1983
New Therapies for Ovarian Cancer
1992
Engineering Chemical Reactivity on Cell Surfaces Through Oligosaccharide Biosynthesis
1997 StandoutScienceNobel
Works of C E Pfeifle being referenced
Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy
1990
Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection.
1983
Clinical pharmacokinetics of intraarterial cisplatin in humans.
1983
Maintenance of Peritoneal Catheter Function by the Intraperitoneal Administration of 32% Dextran 70
1985
Totally implantable system for peritoneal access.
1984
Anaphylactic reaction to cytarabine: In vitro evidence that the response is immunoglobulin e mediated
1984
Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection
1983
Infectious peritonitis in patients receiving intraperitoneal chemotherapy
1985
Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma.
1984
Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma
1986
Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity.
1984
High-dose cisplatin with sodium thiosulfate protection.
1985
Intracavitary cisplatin chemotherapy for mesothelioma.
1985
Pharmacologic Studies of Intra-Hepatic Artery Chemotherapy with Degradable Starch Microspheres
1986
High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose schedule.
1982
High-dose intracavitary cisplatin with intravenous thiosulfate. Low incidence of serious neurotoxicity
1985